-- FactSetが調査したアナリストによると、KalVista Pharmaceuticals（KALV）の平均投資判断は「オーバーウェイト」、平均目標株価は31.60ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Related Articles
International
April S&P Global US Final Manufacturing PMI 54.5 Vs. Unrevised Expected 54.0 Flash, March 52.3
Australia
UBS Adjusts Price Target on LPL Financial to $395 From $380, Maintains Buy Rating
LPL Financial (LPLA) has an average rating of overweight and mean price target of $403, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $320.57, Change: $-13.56, Percent Change: -4.06%
$LPLA
Australia
Morgan Stanley Adjusts Trane Technologies PT to $565 From $535, Maintains Overweight Rating
Trane Technologies (TT) has an average rating of overweight and mean price target of $512.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $494.72, Change: $+2.41, Percent Change: +0.49%
$TT